ClinicalTrials.gg
RecruitingNCT06028828ADAPTUpdated Feb 2, 2026

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

A Phase 2 interventional study of Fludarabine and Melphalan in Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation and Hematologic Malignancies, sponsored by University of California, Irvine. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by University of California, Irvine · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing fludarabine in Hematologic Neoplasms — 11 open to participants now, 12 under way, none of them phase 3. fludarabine · Hematologic Neoplasms.

Planned enrollment
11th of 41
60 · median 32
Started
2023
with 2 others
Phase 2
20 of 41
5 open now
Primary completion
2026-09
later than 1 of 11 live
Registered
33rd of 41
by date

Among the 41 studies testing fludarabine in Hematologic Neoplasms, this one is the 11th largest by planned enrollment, is one of 3 that started in 2023, is one of 20 in phase 2, reaches primary completion later than 1 of the 11 other live ones, and was the 33rd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

11 of the 41 studies testing fludarabine in Hematologic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing fludarabine in Hematologic Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.

Read the detailed description

Eligible patients will receive an allogeneic stem cell transplantation using a combination of fludarabine, melphalan and total body irradiation (TBI) conditioning regimen and post-transplant high dose cyclophosphamide (PTCY), tacrolimus and mycophenolate mofetil (MMF) for graft-versus-host prophylaxis.

Melphalan and TBI doses will be tailored based on the Hematopoietic Stem Cell Transplant- Composite Risk (HCT-CR), age and Karnofski performance status (KPS). Melphalan dose ranges from 100 -140 mg/m2 while TBI dose ranges from 2-5 Gy.

All patients will be monitored for safety and efficacy up to 2 years post-transplantation.

03

Conditions studied

  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Allogeneic Stem Cell Transplantation
  • Hematologic Malignancies

Keywords

  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Allogeneic Stem Cell transplantation
  • AHSCT
  • Hematologic malignancies
  • Melphalan
  • Hematopoietic stem cell transplant -composite risk
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18-70 years
  2. Diagnosis of AML, ALL, MDS, CML, NHL, HD, CLL requiring AHSCT
  3. Has an HLA-matched related (MRD), HLA-matched unrelated (MUD), haploidentical (HAPLO) or 1-Ag mismatched unrelated donor (MMUD)
  4. performance >70%
  5. Adequate major organ system function as demonstrated by:

    1. Serum equal or more than 50 ml/min (calculated with Cockroft-Gault formula).
    2. equal or less than 1.5 mg/dl except for Gilbert's disease. or AST equal or less than 200 IU/ml for adults. Conjugated (direct) bilirubin less than 2x .
    3. equal or greater than 40%.
    4. Diffusing capacity for carbon monoxide (DLCO) equal or greater than 50% predicted corrected for .
  6. Ability to understand and the willingness to sign a written . a. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  1. Inability to comply with medical recommendations or follow-up
  2. Pregnancy
  3. Active/uncontrolled bacterial or viral infection (PI is the final arbiter of this criterion.)
  4. Has active CNS or ocular disease involvement within 3 months
  5. Patients with primary CNS lymphoma
  6. Patients who require modifications of the conditional regimen
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Patients with AML, ALL, MDS, CML, NHL, HD, CLL requiring AHSCT

    Patients will be treated with allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on their Hematopoietic Cell Transplant - Composite Risk (HCT-CR), age, and Karnofski performance status (KPS).

    Drug: Fludarabine · Drug: Melphalan · Radiation: Total Body Irradiation

Interventions

  • Given Day-5, Day-4, Day-3, Day-2

  • Given Day-5

  • RadiationTotal Body Irradiation

    Given Day-1

    Also known as: TBI

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from stem cell infusion to time of disease relapse or death from any cause; data for patients who were alive without relapse will be censored at the date of last contact.

    Time frame: Up to 48 months

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from stem cell infusion until death from any cause. Data of patients who were alive without relapse will be censored at the date of last contact.

    Time frame: Up to 48 months

  2. Cumulative incidence of Graft-Versus-Host-Free, relapse-free survival (GRFS)

    GRFS is defined as time from stem cell infusion to time of the first event among acute GVHD grades 3-4, extensive chronic GVHD, relapse, and death. Data of patients who are event-free will be censored at the date of last contact.

    Time frame: Up to 48 months

  3. Cumulative incidence of relapse

    Relapse is defined as re-occurrence of the disease after stem cell infusion. Cumulative incidence of relapse will be measured from date of stem cell infusion to date of disease relapse. Death without disease relapse is considered a competing risk for relapse. Data of patients who are alive without disease relapse will be censored at the date of last contact.

    Time frame: Up to 48 months

  4. Cumulative incidence of Non-Relapse Mortality (NRM)

    NRM is defined as death related to AHSCT during continuous complete remission. Cumulative incidence of NRM will be measured from date of stem cell infusion to date of death. Disease relapse is considered a competing risk for NRM. Data of patients who are alive without disease relapse will be censored at the date of last contact.

    Time frame: Up to 48 months

  5. Cumulative incidence of acute and chronic graft versus host disease (GVHD)

    Acute and chronic GVHD will be measured from date of stem cell infusion to date of the event. Death without GVHD is considered a competing risk for GVHD. Patients who are alive without GVHD will be censored at the date of last contact.

    Time frame: Up to 48 months

  6. Area Under the Curve (AUC) of Melphalan

    AUC will be used to determine the pharmacokinetic of melphalan after the infusion on D-5. Data will be summarized using descriptive statistics.

    Time frame: From melphalan infusion start time to 22 hours after the infusion.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2026, 36 months after the start.

Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's planned 36 months is below that.

Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Sep 8, 2023
StartActual
Sep 11, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2027
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06028828
Responsible party
Stefan Octavian Ciurea (Professor of Clinical Medicine, University of California, Irvine) — Principal investigator
First posted
Sep 8, 2023
Start date
Sep 11, 2023
Primary completion
Sep 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Feb 2, 2026

Study contacts

Chao Family Comprehensive Cancer Center University of California, Irvine
Contact
ucstudy@uci.edu
1-877-827-8839
University of California Irvine Medical
Contact
Stefan O. Ciurea, MD
principal investigator · Chao Family Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Melphalan

Start the discussion